MetaVia (MTVA) Other Accumulated Expenses (2018 - 2026)
MetaVia's (MTVA) quarterly Other Accumulated Expenses came in at $149000.0 in Q4 2025, up 170.91% YoY from $55000.0 in Q4 2024, and down 95.51% on a QoQ basis from $3.3 million in Q3 2025.
MetaVia (MTVA) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
MetaVia (MTVA) has 8 years of Other Accumulated Expenses data on file, last reported at $149000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses rose 170.91% year-over-year to $149000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $149000.0 (up 170.91% YoY) and the FY2025 annual result came in at $149000.0, up 170.91% from the prior year.
- Other Accumulated Expenses retreated to $149000.0 in Q4 2025, from $3.3 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $3.5 million in Q3 2024 to a low of $12000.0 in Q4 2021.
- A 5-year average of $592166.7 and a median of $51500.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 93.03% — and 2025, when it surged 3553.85%.
- Tracing MTVA's Other Accumulated Expenses over 5 years: stood at $12000.0 in 2021, then jumped by 300.0% to $48000.0 in 2022, then jumped by 1543.75% to $789000.0 in 2023, then plunged by 93.03% to $55000.0 in 2024, then jumped by 170.91% to $149000.0 in 2025.
- The last three Other Accumulated Expenses figures came in at $149000.0 (Q4 2025), $3.3 million (Q3 2025), and $15000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Dec 31, 2025 | 149,000.00 |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 65,000.00 |
| Dec 31, 2023 | 789,000.00 |
| Mar 31, 2023 | 19,000.00 |
| Dec 31, 2022 | 48,000.00 |
| Sep 30, 2022 | 94,000.00 |
| Jun 30, 2022 | 36,000.00 |
| Mar 31, 2022 | 36,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 36,000.00 |
| Mar 31, 2021 | 68,000.00 |
| Dec 31, 2020 | 40,000.00 |